Radovich Peter 4

What Happened

• Peter Radovich, President and COO of Mirum Pharmaceuticals (MIRM), had restricted stock units convert to common stock on Jan 23, 2026 (5,750 shares reported as an exercise/conversion of a derivative). Following the conversion, he sold 3,143 shares in an open-market transaction on Jan 26, 2026 at $96.19 per share, generating $302,331 in proceeds. The Form 4 also records the derivative conversion/ disposition related to the RSU vesting.

Key Details

• Transaction dates: Jan 23, 2026 (conversion/vesting of 5,750 RSUs); Jan 26, 2026 (sale of 3,143 shares).
• Sale price/amount: 3,143 shares @ $96.19 = $302,331.
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1 — each RSU represents a contingent right to one share (or cash); F2 — shares sold to cover tax-withholding obligations tied to RSU vesting; F3 — the RSU award vests 1/3 each year beginning Jan 23, 2024 (fully vested on the three‑year anniversary).
• Filing timing: Form 4 filed Jan 27, 2026 for transactions on Jan 23–26. Form 4s are normally due within two business days of the transaction; this filing was made several days after the Jan 23 vesting event.

Context

• The filing indicates RSUs converted to shares and a subsequent sale to cover tax withholding — a routine, non-speculative event. For retail investors, sales tied to tax-withholding on vested awards are common and do not necessarily signal a change in insider sentiment.